Authors
Stephanie Sanchez-Melendez, Rita Linkner
Published in
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. Nov 10, 2026. Epub Nov 10, 2026.
Abstract
Glucagon-like peptide-1-based therapies have transformed obesity management. Their growing use among perimenopausal and menopausal women introduces new dermatologic considerations, particularly when weight loss occurs alongside menopause-associated changes in skin, adipose tissue, muscle, bone, and hair.
To provide a practical framework for dermatologic management of perimenopausal and menopausal women receiving glucagon-like peptide-1-based therapies.
PubMed was searched from inception through September 2026 for literature on Glucagon-like peptide-1-based therapies, menopause, skin aging, lean mass, alopecia, and aesthetic procedures. Reference lists of relevant reviews and consensus statements were also hand-searched. The senior author, a dermatologist and obesity medicine specialist, provides a practice-based perspective.
Key considerations include weight-loss trajectory, lean mass and bone preservation, nutrition, hair changes, procedural timing, and multidisciplinary comanagement. A staged aesthetic approach prioritizes skin quality during active weight loss, with structural correction as weight stabilizes.
Dermatologic care should anticipate the overlapping effects of menopause and substantial weight loss. A longitudinal, tissue-preservation approach may shift care from reactive correction toward proactive management.
PMID:
43002621
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 13
- Comments 0